Bio-Rad Laboratories (BIO) return on equity (ROE)

Return on equity · fiscal 2025
10.2%

Bio-Rad Laboratories (BIO) earned a return on equity of 10.2% in fiscal 2025 (the year ended December 31, 2025). That is 38.3 percentage points higher than the -28.1% of fiscal 2024. Figures as of 18 Nov 2026, 00:08 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
10.2%
Change on fiscal 2024
+38.3 pts
Highest on record
38.6%fiscal 2020
Lowest on record
-37.7%fiscal 2022
Fiscal years on record
182008–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Bio-Rad Laboratories return on equity (ROE), in more detail

Across the 18 fiscal years on record (2008–2025), the highest was 38.6% in fiscal 2020 and the lowest -37.7% in fiscal 2022. The fiscal 2025 figure is higher than in 65% of the 17 earlier fiscal years on record, whose median is 8.2%.

History · 18 fiscal years

Return on equity by fiscal year

Bio-Rad Laboratories return on equity (ROE), year by year

Bio-Rad Laboratories (BIO) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202510.2% 38.3 pts up
2024-28.1% 20.8 pts down
2023-7.3% 30.4 pts up
2022-37.7% 68.8 pts down
202131.1% 7.5 pts down
202038.6% 8.0 pts up
201930.5% 21.5 pts up
20189.1% 4.9 pts up
20174.2% 3.2 pts up
20161.0% 3.4 pts down
20154.4% 0.3 pts up
20144.1% 0.5 pts up
20133.6% 4.7 pts down
20128.2% 2.1 pts down
201110.3% 1.8 pts down
201012.1% 0.6 pts up
200911.5% 3.1 pts up
20088.4%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Bio-Rad Laboratories and comparable companies
CompanyReturn on equityFiscal year
Vaxcyte PCVX-28.5%2025
Bio-Rad Laboratories BIO10.2%2025
Molina Healthcare MOH11.6%2025
Spyre Therapeutics SYRE-21.7%2025
Qiagen QGEN11.2%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on BIO

Bio-Rad Laboratories, figure by figure

Bio-Rad Laboratories (BIO) overview: price, valuation and scorecardAll health care companies by market value

Bio-Rad Laboratories return on equity (ROE): questions and answers

What is Bio-Rad Laboratories's return on equity?

Bio-Rad Laboratories (BIO) earned a return on equity of 10.2% in fiscal 2025 (the year ended December 31, 2025). That is 38.3 percentage points higher than the -28.1% of fiscal 2024.

Is Bio-Rad Laboratories's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 65% of the 17 earlier fiscal years on record, whose median is 8.2%.

What are the highest and lowest return on equity figures on record for Bio-Rad Laboratories?

Across the 18 fiscal years on record (2008–2025), the highest was 38.6% in fiscal 2020 and the lowest -37.7% in fiscal 2022.

How is Bio-Rad Laboratories's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bio-Rad Laboratories (BIO) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/BIO/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.